Weili Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Weili Wang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Rongrong Wang
Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine
3 shared publications - Tingbo Liang
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
3 shared publications - Wei Zhang
Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China
3 shared publications Li Wang
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou China
2 shared publications- Pingbo Jin
Zhejiang University School of Medicine
2 shared publications - Xinyu Yu
Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People’s Republic of China
2 shared publications
Latest Publications
- 17 August 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (6)
Utility of Low‐Weight Grafts From Young Pediatric Donors in Children Liver Transplantation: Is There a Limit of Whole Graft Weight?
Background: Low‐weight grafts from young pediatric donors are considered a risk factor for surgical complications. However, the limited availability of age‐ and size‐matched organs has prompted a re‐evaluation of low‐weight grafts from young pediatric donors. Methods: From January 1, 2019, to December 31, 2023, 52 pediatric liver transplants receiving young pediatric donors (≤ 2 years old) with low body weight (≤ 15 kg) were performed. According to graft weights (GW), recipients were divided into two groups: Group 1 (GW ≤ 150 g) and Group 2 (GW: 151–400 g), to compare donor and recipient characteristics, postoperative complications, and graft and recipient survival. Results: Group 1 donors were younger (5.4 ± 4.2 vs. 14.4 ± 4.7 months, p < 0.001), smaller in body length (58.0 ± 8.7 vs. 75.7 ± 8.5 cm, p < 0.001), and lighter in weight (6.2 ± 2.8 vs. 10.0 ± 2.0 kg, p < 0.001) compared to Group 2. There were no significant differences in preoperative laboratory tests between groups, and the incidences of vascular complications were also similar between the groups. The 1‐ and 3‐year patient survival rates were 100% and 100% in Group 1 vs. 97% and 97% in Group 2, respectively. The 1‐ and 3‐year graft survival rates were 100% and 91% in Group 1 vs. 97% and 97% in Group 2, with no significant differences. The smallest graft, weighing 86 g, yielded an ideal outcome for the recipient. Conclusions: Low‐weight grafts from young pediatric donors can achieve excellent outcomes and represent a potential strategy to increase donor availability for well‐selected pediatric recipients.
- 17 August 2025
- Published by Wiley in Pediatric Transplantation
- Vol. 29 (6)
Utility of Low‐Weight Grafts From Young Pediatric Donors in Children Liver Transplantation: Is There a Limit of Whole Graft Weight?
Background: Low‐weight grafts from young pediatric donors are considered a risk factor for surgical complications. However, the limited availability of age‐ and size‐matched organs has prompted a re‐evaluation of low‐weight grafts from young pediatric donors. Methods: From January 1, 2019, to December 31, 2023, 52 pediatric liver transplants receiving young pediatric donors (≤ 2 years old) with low body weight (≤ 15 kg) were performed. According to graft weights (GW), recipients were divided into two groups: Group 1 (GW ≤ 150 g) and Group 2 (GW: 151–400 g), to compare donor and recipient characteristics, postoperative complications, and graft and recipient survival. Results: Group 1 donors were younger (5.4 ± 4.2 vs. 14.4 ± 4.7 months, p < 0.001), smaller in body length (58.0 ± 8.7 vs. 75.7 ± 8.5 cm, p < 0.001), and lighter in weight (6.2 ± 2.8 vs. 10.0 ± 2.0 kg, p < 0.001) compared to Group 2. There were no significant differences in preoperative laboratory tests between groups, and the incidences of vascular complications were also similar between the groups. The 1‐ and 3‐year patient survival rates were 100% and 100% in Group 1 vs. 97% and 97% in Group 2, respectively. The 1‐ and 3‐year graft survival rates were 100% and 91% in Group 1 vs. 97% and 97% in Group 2, with no significant differences. The smallest graft, weighing 86 g, yielded an ideal outcome for the recipient. Conclusions: Low‐weight grafts from young pediatric donors can achieve excellent outcomes and represent a potential strategy to increase donor availability for well‐selected pediatric recipients.
- Open Access
- 7 July 2025
- Published by Taylor & Francis in Virulence
- Vol. 16 (1) , 2525929
Comparison of Omicron and respiratory virus infections in pediatric liver transplantation: Impact of perioperative identification status
Peri-operative respiratory virus (RV) infection is critical in paediatric liver transplantation. However, it has been inadequately studied, especially in terms of the clinical latency of infection (incubation period) and Omicron variant infection. Herein, we compared the infection profile of common RVs and Omicron variants in paediatric liver transplantation, aiming to identify the association of virus infection with outcomes. The Omicron cohort was designed prospectively, and the RV cohort was retrospective. Survival outcomes, medical resources, and major complications were compared. Risk factors associated with peri-operative mortality were investigated using regression analysis. We enrolled 649 paediatric liver transplantation patients, including 28 Omicron and 61 RV infections. The 1-y overall survival was 97.7 ± 0.6% for the non-infected group, and 93.4 ± 3.2% for the RV group (p = 0.092). No death occurred in the Omicron group. Mortality was higher in the clinical latency infection group compared with that in the non-infected group (13.8% vs. 1.4%, p = 0.002). Latent RV infection (hazard ratio (HR) = 6.323, 95% confidence interval (CI): 1.374-29.087), Multi‑drug resistance organism pneumonia (HR = 7.177, 95% CI: 1.817-28.350), infectious shock (HR = 4.284, 95% CI: 0.995-18.442) and blood loss (HR = 3.209, 95% CI: 1.166-8.833) were independent risk factors for peri-operative mortality. In conclusion, pre-transplant viral screening is fundamental to paediatric liver transplantation. Peri-operative Omicron infection might be controllable, while RV infection led to more complications compared with those in the non-infected group. Clinical latency infection is the key risk for paediatric liver transplantation mortality.
- 7 July 2025
- Published by Taylor & Francis in Virulence
- Vol. 16 (1) , 2525929
Open AccessComparison of Omicron and respiratory virus infections in pediatric liver transplantation: Impact of perioperative identification status
Peri-operative respiratory virus (RV) infection is critical in paediatric liver transplantation. However, it has been inadequately studied, especially in terms of the clinical latency of infection (incubation period) and Omicron variant infection. Herein, we compared the infection profile of common RVs and Omicron variants in paediatric liver transplantation, aiming to identify the association of virus infection with outcomes. The Omicron cohort was designed prospectively, and the RV cohort was retrospective. Survival outcomes, medical resources, and major complications were compared. Risk factors associated with peri-operative mortality were investigated using regression analysis. We enrolled 649 paediatric liver transplantation patients, including 28 Omicron and 61 RV infections. The 1-y overall survival was 97.7 ± 0.6% for the non-infected group, and 93.4 ± 3.2% for the RV group (p = 0.092). No death occurred in the Omicron group. Mortality was higher in the clinical latency infection group compared with that in the non-infected group (13.8% vs. 1.4%, p = 0.002). Latent RV infection (hazard ratio (HR) = 6.323, 95% confidence interval (CI): 1.374-29.087), Multi‑drug resistance organism pneumonia (HR = 7.177, 95% CI: 1.817-28.350), infectious shock (HR = 4.284, 95% CI: 0.995-18.442) and blood loss (HR = 3.209, 95% CI: 1.166-8.833) were independent risk factors for peri-operative mortality. In conclusion, pre-transplant viral screening is fundamental to paediatric liver transplantation. Peri-operative Omicron infection might be controllable, while RV infection led to more complications compared with those in the non-infected group. Clinical latency infection is the key risk for paediatric liver transplantation mortality.
- Open Access
- 18 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (4) , 631-640
Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-coronavirus disease policy in China: A prospective, observational study
- 18 October 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (4) , 631-640
Open AccessClinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-coronavirus disease policy in China: A prospective, observational study
- Open Access
- 19 August 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
Objective: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC Cmin) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC Cmin post-ERCP and related factors. Methods: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC Cmin measures). The absolute difference and the variation extent in TAC Cmin pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared. Results: The TAC Cmin in LT patients significantly increased in the first three days post-ERCP (p0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher (pmin. The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant. Conclusion: The TAC Cmin significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors.
- 19 August 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Open AccessVariation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
Objective: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC Cmin) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC Cmin post-ERCP and related factors. Methods: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC Cmin measures). The absolute difference and the variation extent in TAC Cmin pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared. Results: The TAC Cmin in LT patients significantly increased in the first three days post-ERCP (p0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher (pmin. The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant. Conclusion: The TAC Cmin significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors.